ALLOVIR, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8 USD | +2.56% |
|
+7.80% | +17.68% |
| Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
| Mar. 15 | AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 87.09M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M | Net income 2025 * | -41M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 129M | Net cash position 2025 * | 220M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.21
x | P/E ratio 2025 * |
-2.26
x | Employees | 112 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on AlloVir, Inc.
More recommendations
More press releases
| 1 day | +2.56% | ||
| 1 week | +7.80% | ||
| Current month | +5.97% | ||
| 1 month | +5.21% | ||
| 3 months | +15.89% | ||
| 6 months | -41.18% | ||
| Current year | +17.68% |
1 week
0.75
0.83
1 month
0.710.85
Current year
0.620.85
1 year
0.626.12
3 years
0.6226.41
5 years
0.6248.96
10 years
0.6248.96
| Managers | Title | Age | Since |
|---|---|---|---|
Juan F. Vera
FOU | Founder | 44 | 13-07-31 |
Ann M. Leen
FOU | Founder | 47 | 13-07-31 |
Diana Brainard
CEO | Chief Executive Officer | 53 | 19-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vikas Sinha
PSD | President | 60 | 18-08-31 |
| Director/Board Member | 57 | 19-04-30 | |
David Hallal
CHM | Chairman | 57 | 18-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 2 M€ | -.--% | ||
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.8 | +2.56% | 564,005 |
| 24-04-24 | 0.78 | -1.38% | 147,469 |
| 24-04-23 | 0.7909 | +3.66% | 280,504 |
| 24-04-22 | 0.763 | +1.71% | 173,849 |
| 24-04-19 | 0.7502 | +1.09% | 341,293 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
5
Last Close Price
0.78
USD
Average target price
1
USD
Spread / Average Target
+28.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.68% | 87.09M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- ALVR Stock
